In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
Hepatitis C virus (HCV) infection is an alarming and growing threat to public health. The present treatment gives limited efficacy and is poorly tolerated, recommending the urgent medical demand for novel therapeutics. NS3/4A protease is a significant emerging target for the treatment of HCV infecti...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3923879?pdf=render |
| _version_ | 1819231814310428672 |
|---|---|
| author | Abdul Wadood Muhammad Riaz Reaz Uddin Zaheer Ul-Haq |
| author_facet | Abdul Wadood Muhammad Riaz Reaz Uddin Zaheer Ul-Haq |
| author_sort | Abdul Wadood |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) infection is an alarming and growing threat to public health. The present treatment gives limited efficacy and is poorly tolerated, recommending the urgent medical demand for novel therapeutics. NS3/4A protease is a significant emerging target for the treatment of HCV infection. This work reports the complex-based pharmacophore modeling to find out the important pharmacophoric features essential for the inhibition of both protease and helicase activity of NS3/4A protein of HCV. A seven featured pharmacophore model of HCV NS3/4A protease was developed from the crystal structure of NS3/4A protease in complex with a macrocyclic inhibitor interacting with both protease and helicase sites residues via MOE pharmacophore constructing tool. It consists of four hydrogen bond acceptors (Acc), one hydrophobic (Hyd), one for lone pair or active hydrogen (Atom L) and a heavy atom feature (Atom Q). The generated pharmacophore model was validated by a test database of seventy known inhibitors containing 55 active and 15 inactive/least active compounds. The validated pharmacophore model was used to virtually screen the ChemBridge database. As a result of screening 1009 hits were retrieved and were subjected to filtering by Lipinski's rule of five on the basis of which 786 hits were selected for further assessment using molecular docking studies. Finally, 15 hits of different scaffolds having interactions with important active site residues were predicted as lead candidates. These candidates having unique scaffolds have a strong likelihood to act as further starting points in the development of novel and potent NS3/4A protease inhibitors. |
| first_indexed | 2024-12-23T11:50:56Z |
| format | Article |
| id | doaj.art-e9383a1f665c4bb4980a88f3717f46e2 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T11:50:56Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e9383a1f665c4bb4980a88f3717f46e22022-12-21T17:48:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e8910910.1371/journal.pone.0089109In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.Abdul WadoodMuhammad RiazReaz UddinZaheer Ul-HaqHepatitis C virus (HCV) infection is an alarming and growing threat to public health. The present treatment gives limited efficacy and is poorly tolerated, recommending the urgent medical demand for novel therapeutics. NS3/4A protease is a significant emerging target for the treatment of HCV infection. This work reports the complex-based pharmacophore modeling to find out the important pharmacophoric features essential for the inhibition of both protease and helicase activity of NS3/4A protein of HCV. A seven featured pharmacophore model of HCV NS3/4A protease was developed from the crystal structure of NS3/4A protease in complex with a macrocyclic inhibitor interacting with both protease and helicase sites residues via MOE pharmacophore constructing tool. It consists of four hydrogen bond acceptors (Acc), one hydrophobic (Hyd), one for lone pair or active hydrogen (Atom L) and a heavy atom feature (Atom Q). The generated pharmacophore model was validated by a test database of seventy known inhibitors containing 55 active and 15 inactive/least active compounds. The validated pharmacophore model was used to virtually screen the ChemBridge database. As a result of screening 1009 hits were retrieved and were subjected to filtering by Lipinski's rule of five on the basis of which 786 hits were selected for further assessment using molecular docking studies. Finally, 15 hits of different scaffolds having interactions with important active site residues were predicted as lead candidates. These candidates having unique scaffolds have a strong likelihood to act as further starting points in the development of novel and potent NS3/4A protease inhibitors.http://europepmc.org/articles/PMC3923879?pdf=render |
| spellingShingle | Abdul Wadood Muhammad Riaz Reaz Uddin Zaheer Ul-Haq In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. PLoS ONE |
| title | In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. |
| title_full | In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. |
| title_fullStr | In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. |
| title_full_unstemmed | In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. |
| title_short | In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. |
| title_sort | in silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of hcv ns3 4a protease using complex based pharmacophore mapping and virtual screening |
| url | http://europepmc.org/articles/PMC3923879?pdf=render |
| work_keys_str_mv | AT abdulwadood insilicoidentificationandevaluationofleadsforthesimultaneousinhibitionofproteaseandhelicaseactivitiesofhcvns34aproteaseusingcomplexbasedpharmacophoremappingandvirtualscreening AT muhammadriaz insilicoidentificationandevaluationofleadsforthesimultaneousinhibitionofproteaseandhelicaseactivitiesofhcvns34aproteaseusingcomplexbasedpharmacophoremappingandvirtualscreening AT reazuddin insilicoidentificationandevaluationofleadsforthesimultaneousinhibitionofproteaseandhelicaseactivitiesofhcvns34aproteaseusingcomplexbasedpharmacophoremappingandvirtualscreening AT zaheerulhaq insilicoidentificationandevaluationofleadsforthesimultaneousinhibitionofproteaseandhelicaseactivitiesofhcvns34aproteaseusingcomplexbasedpharmacophoremappingandvirtualscreening |